Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 inhibitors (SGLT2) are key treatments for type 2 diabetes that improve cardiovascular and renal outcomes [1–3]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.